Product
Pegylated Liposomal Doxorubicin
Aliases
ATI-0918, Caelyx, Doxil, Doxilen, Doxorubicin HCl Liposomal (23 other aliases)
Name
Doxorubicin Hydrochloride Liposome
FDA Approved
Yes
26 clinical trials
1 organization
85 indications
1 document
Indication
Ovarian Serous CarcinomaIndication
Platinum-resistant Ovarian CancerIndication
Fallopian tube cancerIndication
Ovarian CancerIndication
Primary Peritoneal CarcinomaIndication
Primary Peritoneal CancerIndication
CancerIndication
Fallopian Tube NeoplasmsIndication
Primary Peritoneal NeoplasmIndication
Ovarian Cancer RecurrentIndication
Endometrial CancerIndication
fallopian tube carcinomaIndication
Cervical CancerIndication
Advanced Malignant NeoplasmIndication
Colorectal cancerIndication
Liver MetastasisIndication
Malignant NeoplasmIndication
Breast CancerIndication
Triple-Negative Breast CarcinomaIndication
Breast Cancer, Stage IVIndication
Fallopian Tube CarcinomaIndication
Platinum-Refractory Ovarian CarcinomaIndication
Endometrioid AdenocarcinomaIndication
High-Grade Serous AdenocarcinomaIndication
Ovarian Endometrioid AdenocarcinomaIndication
Ovarian High Grade Serous AdenocarcinomaIndication
Platinum-Resistant Ovarian CarcinomaIndication
Ovarian Seromucinous CarcinomaIndication
Recurrent Fallopian Tube CarcinomaIndication
Clear Cell AdenocarcinomaIndication
Recurrent Ovarian CarcinomaIndication
Ovarian Clear Cell AdenocarcinomaIndication
Recurrent Primary Peritoneal CarcinomaIndication
Hodgkin LymphomaIndication
Hodgkin lymphomaIndication
Malignant Solid NeoplasmIndication
Low Grade Serous AdenocarcinomaIndication
Low Grade Serous Ovarian AdenocarcinomaIndication
Ovarian Mucinous AdenocarcinomaIndication
Recurrent Ovarian Seromucinous CarcinomaIndication
High Grade Serous Ovarian AdenocarcinomaIndication
Ovarian Transitional Cell CarcinomaIndication
High Grade Serous AdenocarcinomaIndication
Peritoneal Undifferentiated CarcinomaIndication
Ovarian clear cell adenocarcinomaIndication
Ovarian Endometrioid TumorIndication
Ovarian Serous TumorIndication
Ovarian Undifferentiated CarcinomaIndication
Borderline Ovarian Serous TumorIndication
Micropapillary Serous CarcinomaIndication
Ovarian Serous AdenocarcinomaIndication
Primary Peritoneal Serous AdenocarcinomaIndication
Carcinosarcoma of the Fallopian TubeIndication
Endometrial Endometrioid AdenocarcinomaIndication
Platinum-Sensitive Ovarian CarcinomaIndication
Peritoneal CarcinosarcomaIndication
Recurrent Ovarian CarcinosarcomaIndication
lymphomaIndication
Localized Soft Tissue SarcomaIndication
Endometrioid ovarian adenocarcinomaIndication
LeiomyosarcomaIndication
Metastatic SarcomaIndication
Soft Tissue SarcomaIndication
SarcomaClinical trial
PiSARRO-R: p53 Suppressor Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Phase II Study of Systemic Pegylated Liposomal Doxorubicin Chemotherapy With APR-246Status: Completed, Estimated PCD: 2019-07-10
Clinical trial
An Open-Label, Phase 1b Study of SL-172154 (SIRPα-Fc-CD40L) Administered With Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects With Platinum-Resistant Ovarian CancersStatus: , Estimated PCD: 2024-07-01
Clinical trial
REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) Versus Investigator's Choice (IC) Chemotherapy in Women With Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin, in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerStatus: Completed, Estimated PCD: 2021-03-12
Clinical trial
A Phase Ⅰ/Ⅱ Study of TTI-622 in Combination With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian CancerStatus: Terminated, Estimated PCD: 2024-02-15
Clinical trial
Phase 1 Study of Anti-HB-EGF Monoclonal Antibody KHK2866 as Monotherapy in Subjects With Advanced Solid Tumors and in Combination With Chemotherapy in Ovarian CancerStatus: Terminated, Estimated PCD: 2012-11-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Phase II Clinical Study of IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian CancerStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Phase I Study of the NovoTTF-100L(P) System to Enhance Antitumor Activity in Patients With Predominant Hepatic Metastatic CancerStatus: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Women's Triple-Negative First-Line Study: A Phase II Trial of Liposomal Doxorubicin, Bevacizumab and Everolimus (DAE) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant ChemotherapyStatus: Completed, Estimated PCD: 2023-05-24
Clinical trial
A Pilot, Single-Arm, Phase II Trial of Tamoxifen Plus Pegylated Liposomal Doxorubicin in Patients With Metastatic Triple Negative Breast CancerStatus: Not yet recruiting, Estimated PCD: 2028-06-30
Clinical trial
A Randomized Phase II Trial Comparing the Combination of PI3K Inhibitor Copanlisib (BAY 80-6946) and PARP Inhibitor Olaparib (AZD2281) to Standard Chemotherapy in Patients With Recurrent Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Progressed Through Prior PARP Inhibitor TherapyStatus: Withdrawn, Estimated PCD: 2023-03-17
Clinical trial
A Multicentre, Open-label, Randomised Trial of Neoadjuvant Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast CancerStatus: Recruiting, Estimated PCD: 2024-10-30
Clinical trial
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2023-05-09
Clinical trial
Randomized Phase III Trial of Chemotherapy vs. Pembrolizumab Plus Chemotherapy for Relapsed/Refractory Classical Hodgkin LymphomaStatus: Withdrawn, Estimated PCD: 2028-06-30
Clinical trial
DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior BevacizumabStatus: Active (not recruiting), Estimated PCD: 2023-01-26
Clinical trial
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2020-02-23
Clinical trial
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2019-04-04
Clinical trial
A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase II Study of Doxil (Liposomal Doxorubicin), Cyclophosphamide, Vincristine and Prednisone for AIDS-Related Systemic LymphomaStatus: , Estimated PCD: 2003-04-01
Clinical trial
A Prospective Phase Ib/II Trial of Preoperative Radiotherapy Combined With Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue SarcomaStatus: Recruiting, Estimated PCD: 2024-08-24
Clinical trial
An Open-label Phase 1 of Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Platinum Resistant Epithelial Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2021-03-11
Clinical trial
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube CancersStatus: Completed, Estimated PCD: 2023-04-24
Clinical trial
A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin ( (Doxil®) in Patients With Metastatic Leiomyosarcoma and Other Soft Tissue SarcomasStatus: Recruiting, Estimated PCD: 2025-05-03
Organization
Baxter Healthcare Corporation